Agomab Therapeutics shares drop in Nasdaq debut with valuation at 716 million dollars

Shares of Belgian firm Agomab Therapeutics fell 8% in their Nasdaq debut on Friday. The company reached a valuation of roughly 716 million dollars.

Insights:
Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on February 6, 2026, valuing the Belgium BEBE-based company at $716.4 million. This immediate share decline determined the company's market valuation at listing and indicates the market reception to the debut.
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 6, 2026.  REUTERS/Brendan McDermid
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 6, 2026. REUTERS/Brendan McDermid